Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application.

Ariza ME, Williams MV, Wong HK.

Clin Immunol. 2013 Feb;146(2):131-9. doi: 10.1016/j.clim.2012.12.004. Epub 2012 Dec 20. Review.

PMID:
23314273
2.

[Monoclonal antibodies targeting IL-17A or its receptor in psoriasis: a new therapeutic approach?].

Bonnet MC, Bagot M, Bensussan A.

Med Sci (Paris). 2012 Dec;28(12):1035-7. doi: 10.1051/medsci/20122812004. Epub 2012 Dec 21. French. No abstract available.

3.

Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.

Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR.

Dermatol Online J. 2012 Oct 15;18(10):1. Review.

4.

Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S.

J Am Acad Dermatol. 2014 Jul;71(1):141-50. doi: 10.1016/j.jaad.2013.12.036. Epub 2014 Mar 18. Review.

PMID:
24655820
5.

Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model.

Nakajima K, Kanda T, Takaishi M, Shiga T, Miyoshi K, Nakajima H, Kamijima R, Tarutani M, Benson JM, Elloso MM, Gutshall LL, Naso MF, Iwakura Y, DiGiovanni J, Sano S.

J Immunol. 2011 Apr 1;186(7):4481-9. doi: 10.4049/jimmunol.1000148. Epub 2011 Feb 23. Erratum in: J Immunol. 2011 Dec 1;187(11):6157-8.

6.

Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis.

Nakajima K.

J Dermatol. 2012 Mar;39(3):219-24. doi: 10.1111/j.1346-8138.2011.01458.x. Review.

PMID:
22352845
7.

From bench to bedside--translational research in psoriasis.

Prinz JC.

J Eur Acad Dermatol Venereol. 2010 Oct;24 Suppl 6:1-4. doi: 10.1111/j.1468-3083.2010.03829.x.

PMID:
20831702
8.

Targeting interleukin-22 in psoriasis.

Hao JQ.

Inflammation. 2014 Feb;37(1):94-9. doi: 10.1007/s10753-013-9715-y. Review.

PMID:
23978911
9.

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW.

J Allergy Clin Immunol. 2012 Jul;130(1):145-54.e9. doi: 10.1016/j.jaci.2012.04.024. Epub 2012 Jun 5.

10.

Psoriasis and other Th17-mediated skin diseases.

Tokura Y, Mori T, Hino R.

J UOEH. 2010 Dec 1;32(4):317-28. Review.

PMID:
21226422
11.

Specific targeting of interleukin-23p19 as effective treatment for psoriasis.

Levin AA, Gottlieb AB.

J Am Acad Dermatol. 2014 Mar;70(3):555-61. doi: 10.1016/j.jaad.2013.10.043. Epub 2013 Dec 24. Review.

PMID:
24373779
12.

IL-17 targeted therapies for psoriasis.

Chiricozzi A, Krueger JG.

Expert Opin Investig Drugs. 2013 Aug;22(8):993-1005. doi: 10.1517/13543784.2013.806483. Epub 2013 Jun 3. Review.

PMID:
23731078
13.

Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines.

Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A.

Curr Rheumatol Rep. 2007 Dec;9(6):461-7. Review.

14.

New insights of T cells in the pathogenesis of psoriasis.

Cai Y, Fleming C, Yan J.

Cell Mol Immunol. 2012 Jul;9(4):302-9. doi: 10.1038/cmi.2012.15. Epub 2012 Jun 18. Review.

15.

The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment.

Frleta M, Siebert S, McInnes IB.

Curr Rheumatol Rep. 2014 Apr;16(4):414. doi: 10.1007/s11926-014-0414-y. Review.

PMID:
24570394
16.

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis.

Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W.

Nature. 2007 Feb 8;445(7128):648-51. Epub 2006 Dec 24.

PMID:
17187052
17.

The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies.

Novelli L, Chimenti MS, Chiricozzi A, Perricone R.

Autoimmun Rev. 2014 Jan;13(1):64-9. doi: 10.1016/j.autrev.2013.08.006. Epub 2013 Sep 8. Review.

PMID:
24021172
18.

Rationale and early clinical data on IL-17 blockade in psoriasis.

Nwe SM, Champlain AH, Gordon KB.

Expert Rev Clin Immunol. 2013 Jul;9(7):677-82. doi: 10.1586/1744666X.2013.811034. Review.

PMID:
23899238
19.

Interleukin-20 as a target in psoriasis treatment.

Stenderup K, Rosada C, Worsaae A, Clausen JT, Norman Dam T.

Ann N Y Acad Sci. 2007 Sep;1110:368-81. Review.

PMID:
17911452
20.

IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.

Zhu S, Qian Y.

Clin Sci (Lond). 2012 Jun;122(11):487-511. doi: 10.1042/CS20110496. Review.

PMID:
22324470

Supplemental Content

Support Center